Skip to main content
SpringerLink
Log in

Drug Resistance in African Trypanosomiasis

  • Chapter
Antimicrobial Drug Resistance

Part of the book series: Infectious Disease ((ID))

Human sleeping sickness has been with mankind from its earliest beginnings, and may actually have contributed to the evolutionary split of the hominids from their primate relatives. Drugs against sleeping sickness were among the fi rst targets of the new art and science of chemotherapy that was initiated by Paul Ehrlich and his collaborators at the turn of the last century. Ironically and tragically, sleeping sickness drugs have steadily fallen back on the list of priorities of drug development ever since. In contrast, the disease has rebounded, from its comparative obscurity in the sixties of the last century, to the rampant epidemics that devastate several African countries and threaten scores of others today. The treatment of this re-emerging killer disease is still completely dependent on drugs that were developed between 30 and 80 years ago, none of them satisfactory, all of them toxic, all of them impractical - but all of them in daily use because of the sheer lack of alternatives. The chemotherapy of human sleeping sickness with all its plights has been extensively reviewed in many excellent articles (e.g. (1-6)). The current text, besides summarizing the status quo, also intends to touch on the ever-increasing problem of drug resistance, and will give an outlook into a future that might harbour some justifi able hope for improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Docampo, R. and Moreno, S. (2003) Current chemotherapy of human African trypanosomiasis. Parasitol. Res. 90,S10–S13

    PubMed  Google Scholar 

  2. Bouteille, B., Oukem, O., Bisser, S., and Dumas, M. (2003) Treatment perspectives for human African trypanosomiasis. Fundam. Clin. Pharmacol. 17,171–181

    Article  PubMed  CAS  Google Scholar 

  3. Fairlamb, A. (2003) Chemotherapy of human African trypanosomia-sis: current and future prospects. Trends Parasitol. 19,488–494

    Article  PubMed  CAS  Google Scholar 

  4. Barrett, S. V. and Barrett, M. P. (2000) Anti-sleeping sickness drugs and cancer chemotherapy. Parasitol. Today 16,7–9

    Article  PubMed  CAS  Google Scholar 

  5. Stich, A., Barrett, M. P., and Krishna, S. (2003) Waking up to sleeping sickness. Trends Parasitol. 19,195–197

    Article  PubMed  Google Scholar 

  6. Legros, D., Evans, S., Maiso, F., Enyaru, J. C., and Mbulamberi, D. (1999) Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans. R. Soc. Trop. Med. Hyg. 93,439–442

    Article  PubMed  CAS  Google Scholar 

  7. Ehrlich, P. and Shiga, K. (1904) Farbentherapeutische Versuche bei Trypanosomenerkrankung. Berlin. Klin. Wochenschrift 12,329–362

    Google Scholar 

  8. Collins, J. M., Klecker, R. W., Yarchoan, R., Lane, H. C., Fauci, A. S., Redfield, R. R., Broder, S., and Myers, C. E. (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J. Clin. Pharmacol. 26,22–26

    PubMed  CAS  Google Scholar 

  9. Wellde, B. T., Chumo, D. A., and Reardon, M. J. (1989) Treatment of Rhodesian sleeping sickness in Kenya. Ann. Trop. Med. Parasitol. 66,7–14

    Google Scholar 

  10. El Rayah, I. E., Kaminsky, R., Schmid, C., and El Malik, K. H. (1999) Drug resistance in Sudanese Trypanosoma evansi. Vet. Parasitol. 80,281–287

    Article  PubMed  CAS  Google Scholar 

  11. Lambrecht, G., Braun, K., Damer, M., Ganso, M., Hildebrandt, C., Ullmann, H., Kassack, M. U., and Nickel, P. (2002) Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr. Pharm. Des. 8,2371–2399

    Article  PubMed  CAS  Google Scholar 

  12. Lambrecht, G. (2000) Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. Nauyn Schmiedebergs Arch. Pharmacol. 363,340–350

    Article  Google Scholar 

  13. von Kugelgen, I. and Wetter, A. (2000) Molecular pharmacology of P2Y receptors. Nauyn Schmiedebergs Arch. Pharmacol. 362,310–323

    Article  Google Scholar 

  14. North, R. A. and Surprenant, A. (2000) Pharmacology of cloned P2X receptors. Annu. Rev. Pharmocol. Toxicol. 40,563–580

    Article  CAS  Google Scholar 

  15. Lehmann, N., Krishna, A. G., and Fahmy, K. (2002) Suramin affects coupling of rhodopsin to transducin. Biophys. J. 82,793–802

    Article  PubMed  CAS  Google Scholar 

  16. Chadhi, A., Daeffler, L., Gies, J. P., and Landry, Y. (1998) Drugs interacting with G protein alpha subunits: selectivity and perspectives. Fundam. Clin. Pharmacol. 12,121–132

    Article  Google Scholar 

  17. Papineni, R. V., O'Connell, K. N. M., Zhang, H., Dirksen, R. T., and Hamilton, S. L. (2002) Suramin interacts with the calmodu-lin binding site on the ryanodine receptor, RYR1. J. Biol. Chem. 277,49167–49174

    Article  PubMed  CAS  Google Scholar 

  18. Tan, G. T., Wickramashinge, A., Verma, S., Hughes, S. H., Pezzuto, J. M., Baba, M., and Mohan, P. (1993) Sulfonic acid polymers are potent inhibitors of HIV-1 induced cytopathogenicity and the reverse transcriptases of both HIV-1 and HIV-2. Biochim. Biophys. Acta 1181,183–188

    PubMed  CAS  Google Scholar 

  19. Lewis, W., Day, B. J., and Copeland, W. C. (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2,812–822

    Article  PubMed  CAS  Google Scholar 

  20. Peltier, A. C. and Russell, J. W. (2002) Recent advances in drug-related neuropathies. Curr. Opin. Neurol. 15,633–638

    Article  PubMed  Google Scholar 

  21. Huang, S. S., Koh, H. A., and Huang, J. S. (1997) Suramin enters and accumulates in low pH intracellular compartments of v-sis-transformed NIH 3T3 cells. FEBS Lett. 416,297–301

    Article  PubMed  CAS  Google Scholar 

  22. Avliyakulov, N. K., Lukes, J., Kajava, A. V., Liedberg, B., Lundstrom, I., and Svensson, S. P. (2000) Suramin blocks nucleotide triphosphate binding to ribosomal protein L3 from Trypanoplasma borreli. Eur. J. Biochem. 267,1723–1731

    Article  PubMed  CAS  Google Scholar 

  23. Oehler, C., Kopitz, J., and Cantz, M. (2002) Substrate specificity and inhibitor studies of a membrane-bound ganglioside sialidase isolated from human brain tissue. Biol. Chem. 383,1735–1742

    Article  PubMed  CAS  Google Scholar 

  24. Howes, L. and Jones, R. (2002) Interaction between zona pellucida glycoproteins and sperm proacrosin/acrosin during fertilization. J. Reprod. Immunol. 53,181–192

    Article  PubMed  CAS  Google Scholar 

  25. Hermans, J. M., Haines, D. S., James, P. S., and Jones, R. (2003) Kinetics of inhibition of sperm beta-acrosin activity by suramin. FEBS Lett. 544,119–122

    Article  PubMed  CAS  Google Scholar 

  26. Stein, C. A., LaRocca, R. V., Thomas, R., McAtte, N., and Myers, C. E. (1989) Suramin: an anticancer drug with a unique mechanism of action. J. Clin. Oncol. 7,499–508

    PubMed  CAS  Google Scholar 

  27. Newton, H. B. (2000) Novel chemotherapeutic agents for the treatment of brain cancer. Expert Opin. Investig. Drugs 9,2815–2829

    Article  PubMed  CAS  Google Scholar 

  28. Botta, M., Manetti, F., and Corelli, F. (2000) Fibroblast growth factors and their inhibitors. Curr. Pharm. Des. 6,1897–1924

    Article  PubMed  CAS  Google Scholar 

  29. Raj, P. A., Marcus, E., and Rein, R. (1998) Conformational requirements of suramin to target angiogenic growth factors. Angiogenesis 2,183–199

    PubMed  CAS  Google Scholar 

  30. Fernandez-Tornero, C., Lozano, R. M., Redondo-Horcajo, M., Gomez, A. M., Lopez, J. C., Quesada, E., Uriel, C., Valverde, S., Cuevas, P., Romero, A., and Gimenez-Gallego, G. (2003) Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibro-blast growth factor in complex with 5-amino-2-naphthalene sul-fonate. J. Biol. Chem. 278,21774–21781

    Article  PubMed  CAS  Google Scholar 

  31. Palamakumbura, A., Sommer, P., and Trackman, P. C. (2003) Autocrine growth factor regulation of lysyl oxidase expression in transformed fibroblasts. J. Biol. Chem. 278,30781–30787

    Article  PubMed  CAS  Google Scholar 

  32. Engisch, R., Schurmann, K., Bienert, H., vom Dahl, J., Voss, M., Gunther, R. W., and Vorwerk, D. (2000) Suramin inhibits proliferation of human arterial smooth muscle cells in vitro: potential drug for prevention of restenosis by local drug delivery. J. Vasc. Interv. Radiol. 11,639–644

    Article  PubMed  CAS  Google Scholar 

  33. Stratman, J., Scheer, J., and Ryan, C. A. (2000) Suramin inhibits initiation of defense signaling by systemin, chitosan and a beta-glucan elicitor in suspension-cultured Lycopersicon peruvianum cells. Proc. Natl. Acad. Sci. U.S.A. 97,8862–8867

    Article  Google Scholar 

  34. Sands, M., Kron, M. A., and Brown, R. B. (1985) Pentamidine, a review. Rev. Infect. Dis. 7,625–634

    PubMed  CAS  Google Scholar 

  35. Clement, B. and Jung, F. (1994) N-hydroxylantion of the anti-protozoal drug pentamidine catalyzed by rabbit liver cytochrome P-450 2C3 or human liver microsomes, microsomal retroreduction, and further oxidative transformation of the formed amidoximes. Possible relationship to the biological oxidation of arginine to NG-hydroxyarginine, citrulline and nitric oxide. Drug Metab. Dispos. 22,486–497

    PubMed  CAS  Google Scholar 

  36. Atsriku, C., Watson, D. G., Grant, M. H., and Skellern, G. G. (2003) The effect of inducing agents on the metabolism of trypano-cidal diamidines by isolated rat hepatocytes. Chem. Biol. Interact. 146,297–305

    Article  PubMed  CAS  Google Scholar 

  37. Li, X. Q., Bjorkman, A., Andersson, T. B., Gustafson, L. L., and Masimirembwa, C. M. (2003) Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur. J. Clin. Pharmacol. 59,429–442

    Article  PubMed  CAS  Google Scholar 

  38. Harding, R. D. (1945) Late results of treatment of sleeping sickness in Sierra Leone by antrypol, tryparsamide, pentamidine and propamidine singly and in various combinations. Trans. R. Soc. Trop. Med. Hyg. 39,99–124

    Article  Google Scholar 

  39. Duggan, A. J. and Hutchinson, M. P. (1951) The efficacy of certain trypanocidal compounds against Trypanosoma gambiense infections in man. Trans. R. Soc. Trop. Med. 44,535–544

    Article  CAS  Google Scholar 

  40. Lejon, V., Legros, D., Savignoni, A., Etchegorry, M. G., Mbulamberi, D., and Buescher, P. (2003) Neuro-inflammatory risk factors for treatment failure in “early second stage” sleeping sickness patients treated with Pentamidine. J. Neuroimmunol. 144,132–138

    Article  PubMed  CAS  Google Scholar 

  41. Doua, F., Miezan, T. W., Sanon Singaro, J. R., Boa Yapo, F., and Baltz, T. (1996) The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Am. J. Trop. Med. Hyg. 55,586–588

    PubMed  CAS  Google Scholar 

  42. Bray, P. G., Barrett, M. P., Ward, S. A., and de Koning, H. P. (2003) Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol. 19,232–239

    Article  PubMed  CAS  Google Scholar 

  43. Carter, N. S., Berger, B. J., and Fairlamb, A. H. (1995) Uptake of diamidine drugs by the P2 nucleoside transporter in melarsen-sensitive and -resistant Trypanosoma brucei brucei. J. Biol. Chem. 270,28153–28157

    Article  PubMed  CAS  Google Scholar 

  44. de Koning, H. P. (2001) Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three distinct transporters: implications for cross-resistance with arsenicals. Mol. Pharmacol. 59,586–592

    PubMed  Google Scholar 

  45. Matovu, E., Stewart, M. L., Geiser, F., Brun, R., Maeser, P., Wallace, L. J., Burchmore, R. J., Enyaru, J. C., Barrett, M. P., Kaminsky, R., Seebeck, T., and de Koning, H. P. (2003) Mechanisms of arsenical and diamidine uptake and resistance in Trypanosome brucei. Eukaryot. Cell 2,1003–1008

    Article  PubMed  CAS  Google Scholar 

  46. Ollivier, G. and Legros, D. (2001) Human African trypanosomia-sis: a history of its therapies and their failures. Trop. Med. Int. Health 6,855–863

    Article  PubMed  CAS  Google Scholar 

  47. Labusquiere, R. and Dutertre, J. (1966) The fight against the last foci of human African trypanosomiasis due to T. gambiense. Med. Trop. 26,357–362

    CAS  Google Scholar 

  48. Coelho, A. C., Beverley, S. M., and Cotrim, P. C. (2002) Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol. Biochem. Parasitol. 130,83–90

    Article  CAS  Google Scholar 

  49. Basselin, M., Denise, H., Coombs, G. H., and Barrett, M. P. (2002) Resistance to pentamidine in Leishmania mexicana involves exclusion of the drug from the mitochondrion. Antimicrob. Agents Chemother. 46,3731–3738

    Article  PubMed  CAS  Google Scholar 

  50. Reinert, K. E. (1999) DNA multimode interaction with berenil and pentamidine: double helix stiffening, unbending and bending. J. Biomol. Struct. Dyn. 17,311–331

    PubMed  CAS  Google Scholar 

  51. Turner, P. R. and Denny, W. A. (1996) The mutagenic properties of DNA minor groove binding ligands. Mutat. Res. 355,141–169

    PubMed  Google Scholar 

  52. Zhang, Y., Li, Z., Pilch, D. S., and Leibowitz, M. J. (2002) Pentamidine inhibits catalytic activity of group I intron Ca.LSU by altering RNA folding. Nucleic Acids Res. 30,2961–2971

    Article  PubMed  CAS  Google Scholar 

  53. Zhang, Y., Bell, A., Perlman, P. S., and Leibowitz, M. (2000) Pentamidine inhibits mitochondrial intron splicing andtranslation in Saccaromyces cerevisiae. RNA 6,937–951

    Article  PubMed  CAS  Google Scholar 

  54. Williams, K., Dattilo, M., Sabado, T. N., Kashiwaga, K., and Igarashi, K. (2003) Pharmacology of the delta2 glutamate receptors: effects of pentamidine and protons. J. Pharmacol. Exp. Ther. 305,740–748

    Article  PubMed  CAS  Google Scholar 

  55. Reynolds, I. J. and Aizenmann, E. (1992) Pentamidine is an N-methyl-D-aspartate receptor antagonist and is neuroprotective in vitro. J. Neurosci. 12,970–975

    PubMed  CAS  Google Scholar 

  56. Pathak, M. K., Dhawan, D., Lindner, D. J., Borden, E. C., Farver, C., and Yi, T. (2002) Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol. Cancer Ther. 1,1255–1264

    PubMed  CAS  Google Scholar 

  57. Friedheim, E. A. H. (1949) MelB in the treatment of human trypanosomiasis. Am. J. Trop. Med. 29,173–180

    CAS  Google Scholar 

  58. Vilensky, J. A. and Redman, K. (2003) British anti-Lewisite (dimercaprol): an amazing history. Ann. Emerg. Med. 41,378–383

    Article  PubMed  Google Scholar 

  59. Zvirblis, P. and Ellin, R. I. (1976) Acute systemic toxicity of pure dimercaprol and trimercaptopropane. Toxicol. Appl. Pharmacol. 36,297–299

    Article  PubMed  CAS  Google Scholar 

  60. Apted, F. I. C. (1970) Treatment of human trypanosomiasis, in The African Trypanosomiases (Mulligan. H. W., ed.) George Allen, London, pp. 684–710

    Google Scholar 

  61. Burri, C., Nkunku, S., Merolle, A., Smith, T., Blum, J., and Brun, P. (2000) Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 355,1419–1425

    Article  PubMed  CAS  Google Scholar 

  62. Blum, J., Nkunku, S., and Burri, C. (2001) Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment in human African trypanosomiasis. Trop. Med. Int. Health 6,390–400

    Article  PubMed  CAS  Google Scholar 

  63. Matovu, E., Enyaru, J. C., Legros, D., Schmid, C., Seebeck, T., and Kaminsky, R. (2001) Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Trop. Med. Int. Health 6,407–411

    Article  PubMed  CAS  Google Scholar 

  64. Brun, R., Schumacher, R., Schmid, C., Kunz, C., and Burri, C. (2001) The phenomenon of treatment failures in human African trypanosomiasis. Trop. Med. Int. Health 6,906–914

    Article  PubMed  CAS  Google Scholar 

  65. Matovu, E., Geiser, F., Schneider, V., Maeser, P., Enyaru, J. C., Kaminsky, R., Gallati, S., and Seebeck, T. (2001) Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Mol. Biochem. Parasitol. 117,73–81

    Article  PubMed  CAS  Google Scholar 

  66. Carter, N. S. and Fairlamb, A. H. (1993) Arsenical-resistant trypanosomes lack an unusual adenosine transporter. Nature 361,173–175

    Article  PubMed  CAS  Google Scholar 

  67. Denise, H. and Barrett, M. P. (2001) Uptake and mode of action of drugs used against sleeping sickness. Biochem. Pharmacol. 61,1–5

    Article  PubMed  CAS  Google Scholar 

  68. Maeser, P., Suetterlin, C., Kralli, A., and Kaminsky, R. (1999) A nucleoside transporter from Trypanosoma brucei involved in drug resistance. Science 285,242–244

    Article  Google Scholar 

  69. Pospichal, H., Brun, R., Kaminsky, R., and Jenni, L. (1994) Induction of resistance to melarsenoxide cysteamine (MelCy) in Trypanosoma brucei brucei. Acta Trop. 58,187–197

    Article  PubMed  CAS  Google Scholar 

  70. Shahi, S. K., Krauth-Siegel, R. L., and Clayton, C. E. (2002) Overexpression of the putative thiol conjugate transporter TbMPRA causes melarsoprol resistance in Trypanosoma brucei. Mol. Microbiol. 43,1129–1138

    Article  PubMed  CAS  Google Scholar 

  71. Ratnaike, R. N. (2003) Acute and chronic arsenic toxicity. Postgrad. Med. J. 79,391–396

    Article  PubMed  CAS  Google Scholar 

  72. Rousselot, P., Labaume, S., Marolleau, J. P., Larghero, J., Noguera, M. H., Brouet, J. C., and Fermand, J. P. (1999) Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 59,1041–1048

    PubMed  CAS  Google Scholar 

  73. Koenig, A., Wrazel, J., Warrell, R. P., Pandolfi, P. P., Jakubowski, A., and Gabrilove, J. L. (1997) Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 2,562–570

    Google Scholar 

  74. Wallace, H. M., Fraser, A. V., and Hughes, A. (2003) A perspective of polyamine metabolism. Biochem. J. 376,1–14

    Article  PubMed  CAS  Google Scholar 

  75. Metcalf, B., Bey, P., Danzin, C., Jung, M. J., Casara, P., and Vevert, J. P. (1978) Catalytic irreversible inhibition of mammalian ornithin decarboxylase (E.C.4.1.1.17) by substrate and product analogues. J. Am. Chem. Soc. 100,2551–2553

    Article  CAS  Google Scholar 

  76. Mamont, P. S., Duchesne, M. C., Grove, J., and Bey, P. (1978) Antiproliferative properties of DL-alpha-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylase. Biochem. Biophys. Res. Commun. 81,58–66

    Article  PubMed  CAS  Google Scholar 

  77. Bacchi, C. J., Nathan, H. C., Hutner, S. H., McCann, P. P., and Sjoerdsma, A. (1980) Polyamine metabolism: a potential therapeutic target in trypanosomes. Science 210,332–334

    Article  PubMed  CAS  Google Scholar 

  78. Burri, C. and Brun, R. (2003) Eflornithine for the treatment of human African trypanosomiasis. Parasitol. Res. 90,S49–52

    PubMed  Google Scholar 

  79. Burchmore, R. J., Ogbunude, P. O., Enanga, B., and Barrett, M. P. (2002) Chemotherapy of human African trypanosomiasis. Curr. Pharm. Des. 8,256–267

    Article  PubMed  Google Scholar 

  80. Iten, M., Matovu, E., Brun, R., and Kaminsky, R. (1995) Innate lack of susceptibility of Ugandan Trypanosoma brucei rhode-siense to DL-alpha-difluoromethyl ornithine. Trop. Med. Parasitol. 46,190–194

    PubMed  CAS  Google Scholar 

  81. Iten, M., Mett, H., Evans, A., Enyaru, J. C., Brun, R., and Kaminsky, R. (1997) Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhode-siense to D, L-alpha-difluoromethyl ornithine. Antimicrob. Agents Chemother. 41,1922–1925

    PubMed  CAS  Google Scholar 

  82. Ehrlich, P. (1907) Chemotherapeutische Trypanosomen-Studien. Berliner klinische Wochenschrift 11,310–314

    Google Scholar 

  83. Kremsner, P. G., Luty, A. J. F., and Graninger, W. (1997) Combination chemotherapy for Plasmodium falciparum malaria. Parasitol. Today 13,167–168

    Article  PubMed  CAS  Google Scholar 

  84. Fulton, J. D. and Yorke, W. (1942) Further observations on the stability of drug-resistance in Trypanosomes. Ann. Trop. Med. Parasitol. 35,221–227

    Google Scholar 

  85. Williamson, J. (1970) Review of chemotherapeutic and che-moprophylactic agents, in The African Trypanosomes (Mulligan, H. W., ed.) George Allen, London, pp. 125–221

    Google Scholar 

  86. Barrett, M. P. (2001) Veterinary link to drug resistance in human African trypanosomiasis? Lancet 358,603–604

    Article  PubMed  CAS  Google Scholar 

  87. Whiteside, E. F. (1962) The control of cattle trypanosomiasis with drugs in Kenya: methods and costs. E. Afr. Agric. J. 28,67

    Google Scholar 

  88. Witola, W. H., Inoue, N., Ohashi, K., and Onuma, M. (2004) RNA-interference silencing of the adenosine transporter-1 gene in Trypanosoma evansi confers resistance to diminazene acetu-rate. Exp. Parasitol. 107,47–57

    Article  PubMed  CAS  Google Scholar 

  89. Beverley, S. M., Coderre, J. A., Santi, D. V., and Schimke, R. T. (1984) Unstable DNA amplifications in methotrexate-resistant Leishmania consist of extrachromosomal circles which relocalize during stabilization. Cell 38,431–439

    Article  PubMed  CAS  Google Scholar 

  90. Ouellette, M., Fase-Fowler, F., and Borst, P. (1990) The amplified H-circle of methotrexate-resistant Leishmania tarentolae contains a novel P-glycoprotein. EMBO J. 9,1027–1033

    PubMed  CAS  Google Scholar 

  91. Wilson, K., Berens, R. L., Sifri, C. D., and Ullman, B. (1994) Amplification of the inosinate dehydrogenase gene in Trypanosoma brucei gambiense due to an increase in chromosome copy number. J. Biol. Chem. 269,28979–28987

    PubMed  CAS  Google Scholar 

  92. Matovu, E., Iten, M., Enyaru, J. C. K., Schmid, C., Lubega, G. W., Brun, R., and Kaminsky, R. (1997) Susceptibility of Ugandan Trypanosoma brucei rhodesiense isolated from man and animal reservoirs to diminazene, isometamidium and melar-soprol. Trop. Med. Int. Health 2,13–18

    Article  PubMed  CAS  Google Scholar 

  93. Zhang, Z. Q., Giroud, C., and Baltz, T. (1993) Trypanosoma evansi: In vivo and in vitro determination of trypanocide resistance profiles. Exp. Parasitol. 77,387–394

    Article  PubMed  CAS  Google Scholar 

  94. Olbrich, C., Gessenr, A., Kayser, O., and Müller, R. H. (2002) Lipid-drug-conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazene acetu-rate. J. Drug Target. 10,387–396

    Article  PubMed  CAS  Google Scholar 

  95. Chauviere, G., Bouteille, B., Enanga, B., de Albuquerque, C., Croft, S. L., Dumas, M., and Périé, J. (2003) Synthesis and biological activity of nitro heterocycles analogous to megazol, a trypanocidal lead. J. Med. Chem. 46,427–440

    Article  PubMed  CAS  Google Scholar 

  96. Darsaud, A., Chevrier, C., Bourdon, L., Dumas, M., Buguet, A., and Bouteille, B. (2004) Megazol combined with suramin improves a new diagnosis of the early meningo-encephalitic phase of experimental African trypanosomiasis. Trop. Med. Int. Health 9,83–91

    Article  PubMed  CAS  Google Scholar 

  97. Nwaka, S. and Ridley, R. G. (2003) Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug. Discov. 2,919–928

    Article  PubMed  CAS  Google Scholar 

  98. Hopkins, A. L. and Groom, C. R. (2002) The druggable genome. Nat. Rev. Drug. Discov. 1,727–730

    Article  PubMed  CAS  Google Scholar 

  99. Cornish-Bowden, A. and Cardenas, M. L. (2003) Metabolic analysis in drug design. C. R. Biol. 326,509–515

    Article  PubMed  CAS  Google Scholar 

  100. Clerici, F., Gelmi, M. L., Yokoyama, K., Pocar, D., Van Voorhis, W. C., Buckner, F. S., and Gelb, M. H. (2002) Isothiazole dioxides: synthesis and inhibition of Trypanosoma brucei protein farnesyltransferase. Bioorg. Med. Chem. Lett. 12,2217–2220

    Article  PubMed  CAS  Google Scholar 

  101. Ohkanda, J., Buckner, F. S., Lockman, J. W., Yokoyama, K., Carrico, D., Eastman, R., de Luca-Fradley, K., Davies, W., Croft, S. L., Van Voorhis, W. C., Gelb, M. H., Sebti, S. M., and Hamilton, A. D. (2004) Design and synthesis of peptidomimetic protein farnesyltransferase inhibitors as anti-Trypanosoma brucei agents. J. Med. Chem. 47,432–445

    Article  PubMed  CAS  Google Scholar 

  102. Montalvetti, A., Fernandez, A., Sanders, J. M., Ghosh, S., Van Brussel, E., Oldfield, E., and Docampo, R. (2003) Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J. Biol. Chem. 278,17075–17083

    Article  PubMed  CAS  Google Scholar 

  103. Martin, M. B., Sanders, J. M., Kendrick, H., de Luca-Fradley, K., Lewis, J. C., Grimley, J. S., Van Brussel, E. M., Olsen, J. R., Meints, G. A., Burzynska, A., Kafarski, P., Croft, S. L., and Oldfield, E. (2002) Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J. Med. Chem. 45,2904–2914

    Article  PubMed  CAS  Google Scholar 

  104. Price, H. P., Menon, M. R., Panethymitaki, C., Goulding, D., McKean, P. G., and Smith, D. I. (2002) Myristoyl-CoA: protein N-myristoyltransferase, an essential enzyme and potential drug target in kinetoplastid parasites. J. Biol. Chem. 278,7206–7214

    Article  PubMed  Google Scholar 

  105. Vial, H., Eldin, P., Tielens, A. G., and van Hellemond, J. J. (2003) Phospholipids in parasitic protozoa. Mol. Biochem. Parasitol. 126,143–154

    Article  PubMed  CAS  Google Scholar 

  106. Roberts, C. W., McLeod, R., Rice, D. W., Ginger, M., Chance, M. l., and Goad, L. J. (2003) Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosoma-tid parasites. Mol. Biochem. Parasitol. 126,129–142

    Article  PubMed  CAS  Google Scholar 

  107. Morita, Y. S., Paul, K. S., and Englund, P. T. (2000) Specialized fatty acid synthesis in African trypanosomes: myristate for GPI anchors. Science 288,140–143

    Article  PubMed  CAS  Google Scholar 

  108. Croft, S. L., Seifert, K., and Duchene, M. (2003) Antiprotozoal activities of phospholipid analogues. Mol. Biochem. Parasitol. 126,165–172

    Article  PubMed  CAS  Google Scholar 

  109. Zoraghi, R. and Seebeck, T., (2002) The cAMP-specific phos-phodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma brucei. Proc. Natl. Acad. Sci. U.S.A. 99,4343–4348

    Article  PubMed  CAS  Google Scholar 

  110. Zoraghi, R., Kunz, S., and Gong, K.-W. S., T. (2001) Characterization of TbPDE2A, a novel cyclic-nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei. J. Biol. Chem. 276,11559–11566

    Article  PubMed  CAS  Google Scholar 

  111. Rascon, A., Soderling, S. H., Schaefer, J. B., and Beavo, J. A. (2002) Cloning and characterization of a cAMP-specific phos-phodiesterase (TbPDE2B) from Trypanosoma brucei. Proc. Natl. Acad. Sci. U.S.A. 99,4714–4719

    Article  PubMed  CAS  Google Scholar 

  112. Kunz, S., Klöckner, T., Essen, L. O., Seebeck, T., and Boshart, M. (2004) TbPDE1, a novel class phosphodiesterase of Trypanosoma brucei. Eur. J. Biochem. 271,637–647

    Article  PubMed  CAS  Google Scholar 

  113. Verlinde, C. L. M. J., Hannaert, V., Blonski, C., Willson, M., Périé, J. J., Fothergill-Gilmore, L. A., Opperdoes, F. R., Gelb, M. H., Hol, W. G. J., and Michels, P. A. M. (2001) Glycolysis as a target for the design of new anti-trypanosomal drugs. Drug Res. Updates 4,50–65

    Article  CAS  Google Scholar 

  114. Schmidt, A. and Krauth-Siegel, R. L. (2002) Enzymes of the trypanothione metabolism as targets fo antitrypanosomal drugs. Curr. Top. Med. Chem. 2,1239–1259

    Article  PubMed  CAS  Google Scholar 

  115. Krieger, S., Schwarz, W., Arianayagam, M. R., Fairlamb, A. H., Krauth-Siegel, R. L., and Clayton, C. (2000) Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress. Mol. Microbiol. 35,542–552

    Article  PubMed  CAS  Google Scholar 

  116. Roper, J. R., Guther, M. L., Milne, K. G., and Ferguson, M. A. (2002) Galactose metabolism is essential for the African sleeping sickness parasite Trypanosoma brucei. Proc. Natl. Acad. Sci. U.S.A. 99,5884–5889

    Article  PubMed  CAS  Google Scholar 

  117. Chang, T., Milne, K. G., Guther, M. l., Smith, T. K., and Ferguson, M. A. (2002) Cloning of Trypanosoma brucei and Leishmania major genes encoding the GlcNAc-phosphatidylinositol de-N-acetylase of glycosylphosphatidylinositol biosynthesis that is essential to the African sleeping sickness parasite. J. Biol. Chem. 277,50176–50182

    Article  PubMed  CAS  Google Scholar 

  118. Shaw, M. P., Bond, C. S., Roper, J. R., Gourley, D. G., Ferguson, M. A., and Hunter, W. N. (2003) High-resolution crystal structure of Trypanosoma brucei UDP-galactose 4′-epimerase: a potential target for structure-based development of novel trypanocides. Mol. Biochem. Parasitol. 126,173–180

    Article  PubMed  CAS  Google Scholar 

  119. Smith, T. K., Crossman, A., Borissow, C. N., Paterson, M. J., Dix, A., Brimacombe, J. S., and Ferguson, M. A. (2001) Specificity of GlcNAc-PI de-N-acetylase of GPI biosynthesis and synthesis of parasite-specific suicide substrate inhibitors. EMBO J. 20,3322–3332

    Article  PubMed  CAS  Google Scholar 

  120. Donkor, I. O., Huang, T. L., Tao, B., Rattendi, D., Lane, S., Vargas, M., Goldberg, B., and Bacchi, C. (2003) Trypanocidal activity of conformationally restricted pentamidine congeners. J. Med. Chem. 46,1041–1048

    Article  PubMed  CAS  Google Scholar 

  121. Brun, R., Burri, C., and Gichuki, C. W. (2001) The story of CGP 40 215: studies on its efficacy and pharmacokinetics in African green monkey infected with Trypanosoma brucei rhodesiense. Trop. Med. Int. Health. 6,362–368

    Article  PubMed  CAS  Google Scholar 

  122. Gertsch, J., Tobler, R. T., Brun, R., Sticher, O., and Heilmann, J. (2003) Antifungal, antiprotozoal, cytotoxic and piscicidal properties of Justicidin B and a new arylnaphthalide lignan from Phyllantus piscatorum. Planta Med. 69,420–424

    Article  PubMed  CAS  Google Scholar 

  123. Camacho, M. R., Philipson, J. D., Croft, S. L., Solis, P. N., Marshall, S. J., and Ghazanfar, A. (2003) Screening of plant extracts for antiprotozoal and cytotoxic activities. J. Ethnopharmacol. 89,185–191

    Article  PubMed  CAS  Google Scholar 

  124. Kamnaing, P., Tsompo, A., Tanifum, E. A., Tchuendem, M. H., Ayafor, H., Werner, O., Rattendi, D., Iwu, M. M., Schuster, B., and Bacchi, C. (2003) Trypanocidal diarylheptanoids from Aframomum letestuianum. J. Nat. Prod. 66,364–367

    Article  PubMed  CAS  Google Scholar 

  125. Nihei, C., Fukai, Y., and Kita, K. (2002) Trypanosome alternative oxidase as a target of chemotherapy. Biochim. Biophys. Acta. 1587,234–239

    PubMed  CAS  Google Scholar 

  126. Freiburghaus, F., Ogwal, E. N., Nkunya, M. H., Kaminsky, R., and Brun, R. (1996) In vitro antitrypanosomal activity of African plants used in traditional medicine in Uganda to treat sleeping sickness. Trop. Med. Int. Health 1,765–771

    PubMed  CAS  Google Scholar 

  127. Freiburghaus, F., Steck, A., Pfander, H., and Brun, R. (1998) Bioassay-guided isolation of a diastereoisomer of kolavenol from Entada abyssinica active on Trypanosoma brucei rhodesiense. J. Ethnopharmacol. 61,179–183

    Article  PubMed  CAS  Google Scholar 

  128. Frommel, T. O. and Balber, A. E. (1987) Flow cytofluori-metric analysis of drug accumulation by multidrug-resistant Trypanosoma brucei brucei and T. b. rhodesiense. Mol. Biochem. Parasitol. 26,183–192

    Article  PubMed  CAS  Google Scholar 

  129. Scott, A. G., Tait, A., and Turner, C. M. R. (1997) Trypanosoma brucei: lack of cross-resistance to melarsoprol in vitro by cymelarsan-resistant parasites. Exp. Parasitol. 86,181–190

    Article  PubMed  CAS  Google Scholar 

  130. Rollo, I. M. and Williamson, J. (1951) Acquired resistance to ‘melarsen’, tryparsamide and amidines in pathogenic trypanosomes after treatment with ‘melarsen’ alone. Nature 167,147–148

    Article  PubMed  CAS  Google Scholar 

  131. Ross, C. A. and Barns, A. M. (1996) Alteration to one of three adenosine transporters is associated with resistance to Cymelarsan in Trypanosoma evansi. Parasitol. Res. 82,183–188

    Article  PubMed  CAS  Google Scholar 

  132. Barrett, M. P., Zhang, Z. Q., Denise, H., Giroud, C., and Baltz, T. (1995) A diamidine-resistant Trypanosoma equiperdum clone contains a P2 purine transporter with reduced substrate affinity. Mol. Biochem. Parasitol. 73,223–229

    Article  PubMed  CAS  Google Scholar 

  133. Fulton, J. D. and Grant, P. T. (1955) The preparation of a strain of Trypanosoma rhodesiense resistant to stilbamidine and some observations on its nature. Ann. Trop. Med. Parasitol. 49,377–387

    Google Scholar 

  134. Zhang, Z. Q., Giroud, C., and Baltz, T. (1991) In vivo and in vitro sensitivity of Trypanosoma evansi and T. equiperdum to dimina-zene, suramin, MelCy, quinapyramine and isometamidium. Acta Trop. 50,101–110

    Article  PubMed  CAS  Google Scholar 

  135. Osman, A. S., Jennings, F. W., and Holmes, P. H. (1992) The rapid development of drug-resistance by Trypanosoma evansi in immunosuppressed mice. Acta Trop. 50,249–257

    Article  PubMed  CAS  Google Scholar 

  136. Desquesnes, M., de La Rocque, S., and Peregrine, A. S. (1995) French Guyanan stock of Trypanosoma vivax resistant to dimi-nazene aceturate but sensitive to isometamidium chloride. Acta Trop. 60,133–136

    Article  PubMed  CAS  Google Scholar 

  137. Joshua, R. A., Obwolo, M. J., Bwangamoi, O., and Mandebvu, E. (1995) Resistance to diminazine aceturate by Trypanosoma congolense from cattle in the Zambezi Valley of Zimbabwe. Vet. Parasitol. 60,1–6

    Article  PubMed  CAS  Google Scholar 

  138. Berger, B. J., Carter, N. S., and Fairlamb, A. H. (1995) Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Mol. Biochem. Parasitol. 69,289–298

    Article  PubMed  CAS  Google Scholar 

  139. Brun, R. and Lun, Z. R. (1994) Drug sensitivity of Chinese Trypanosoma evansi and Trypanosoma equiperdum isolates. Vet. Parasitol. 52,37–46

    Article  PubMed  CAS  Google Scholar 

  140. Gray, M. A., Kimarua, R. W., Peregrine, A. S., and Stevenson, P. (1993) Drug sensitivity screening in vitro of populations of Trypanosoma congolense originating from cattle and tsetse flies at Nguruman, Kenya. Acta Trop. 55,1–9

    Article  PubMed  CAS  Google Scholar 

  141. Moloo, S. K. and Kutuza, S. B. (1990) Expression of resistance to isometamidium and diminazene in Trypanosoma congolense in Boran cattle infected by Glossina morsitans centralis. Acta Trop. 47,79–89

    Article  PubMed  CAS  Google Scholar 

  142. Schonefeld, A., Rottcher, D., and Moloo, S. K. (1987) The sensitivity to trypanocidal drugs of Trypanosoma vivax isolated in Kenya and Somalia. Trop. Med. Parasitol. 38,177–180

    PubMed  CAS  Google Scholar 

  143. Scott, A. G., Tait, A., and Turner, M. R. (1996) Characterisation of cloned lines of Trypanosoma brucei expressing stable resistance to MelCy and Suramin. Acta Trop. 60,251–262

    Article  PubMed  CAS  Google Scholar 

  144. Fairlamb, A. H., Carter, N. S., Cunningham, M., and Smith, K. (1992) Characterisation of melarsen-resistant Trypanosoma bru-cei brucei with respect to cross-resistance to other drugs and trypanothione metabolism. Mol. Biochem. Parasitol. 53,213–222

    Article  PubMed  CAS  Google Scholar 

  145. Afewerk, Y., Clausen, P. H., Abebe, G., Tilahun, G., and Mehlitz, D. (2000) Multiple-drug resistant Trypanosoma congo-lense populations in village cattle of Metekel district, north-west Ethiopia. Acta Trop. 76,231–238

    Article  PubMed  CAS  Google Scholar 

  146. Peregrine, A. S., Gray, M. A., and Moloo, S. K. (1997) Cross-resistance associated with development of resistance to iso-metamidium in a clone of Trypanosoma congolense. Antimicrob. Agents Chemother. 41,1604–1606

    PubMed  CAS  Google Scholar 

  147. Mulugeta, W., Wilkes, J., Mulatu, W., Majiwa, P. A., Masake, R., and Peregrine, A. S. (1997) Long-term occurrence of Trypanosoma congolense resistant to diminazene, isometa-midium and homidium in cattle at Ghibe, Ethiopia. Acta Trop. 64,205–217

    Article  PubMed  CAS  Google Scholar 

  148. Ndoutamia, G., Moloo, S. K., Murphy, N. B., and Peregrine, A. S. (1993) Derivation and characterization of a quinapyramine-resistant clone of Trypanosoma congolense. Antimicrob. Agents Chemother. 37,1163–1166

    PubMed  CAS  Google Scholar 

  149. Codjia, V., Mulatu, W., Majiwa, P. A., Leak, S. G., Rowlands, G. J., Authie, E., d'Ieteren, G. D., and Peregrine, A. S. (1993) Epidemiology of bovine trypanosomiasis in the Ghibe valley, southwest Ethiopia. 3. Occurrence of populations of Trypanosoma congolense resistant to diminazene, isometamidium and homid-ium. Acta Trop. 53,151–163

    Article  PubMed  CAS  Google Scholar 

  150. Clausen, P. H., Sidibe, I., Kabore, I., and Bauer, B. (1992) Development of multiple drug resistance of Trypanosoma congo-lense in Zebu cattle under high natural tsetse fly challenge in the pastoral zone of Samorogouan, Burkina Faso. Acta Trop. 51,229–236

    Article  PubMed  CAS  Google Scholar 

  151. Ainanshe, O. A., Jennings, F. W., and Holmes, P. H. (1992) Isolation of drug-resistant strains of Trypanosoma congolense from the lower Shabelle region of southern Somalia. Trop. Anim. Health Prod. 24,65–73

    Article  PubMed  CAS  Google Scholar 

  152. Peregrine, A. S., Knowles, G., Ibitayo, A. I., Scott, J. R., Moloo, S. K., and Murphy, N. B. (1991) Variation in resistance to iso-metamidium chloride and diminazene aceturate by clones derived from a stock of Trypanosoma congolense. Parasitology 102 (Pt 1),93–100

    Article  Google Scholar 

  153. Chitambo, H. and Arakawa, A. (1991) Therapeutic effect of Berenil and Samorin in mice infected with four trypanosome populations isolated from Zambian cattle. Vet. Parasitol. 39,43–52

    Article  PubMed  CAS  Google Scholar 

  154. WHO (2002) Human African trypanosomiasis. A guide for drug supply

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cell Biology, University of Bern, Bern, Switzerland

    Thomas Seebeck

  2. Institute of Cell Biology, University of Bern, Bern, Switzerland

    Pascal Mäser

Authors
  1. Thomas Seebeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pascal Mäser
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Executive Vice President & Chief Medical Offi cer, Idenix Pharmaceuticals, Cambridge, MA, USA

    Douglas L. Mayers MD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Seebeck, T., Mäser, P. (2009). Drug Resistance in African Trypanosomiasis. In: Mayers, D.L. (eds) Antimicrobial Drug Resistance. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-59745-180-2_42

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-180-2_42

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-592-7

  • Online ISBN: 978-1-59745-180-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation